drugset / Trial / NCT06511037
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
Phase 0
Recruiting
10 enrolled
University of California, Irvine
On Target Laboratories, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pafolacianine | Diagnostic / imaging agent | 0.025 mg/kg | Intravenous |